Anti-CLEC12A/CD371 Antibody (Tepoditamab)
Catalog No.
F1348
Anti-CLEC12A/CD371 Antibody (Tepoditamab)
Featured Products
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A on bone marrow cells and CD3 on cytotoxic T cells. CLEC12A is a bone marrow differentiation antigen. Tepoditamab (MCLA-117) can kill AML leukemia blasts and AML leukemia stem cells, induce T cell-mediated proliferation and lysis of acute myeloid cells, and can be used in acute myeloid leukemia (AML) research.
144.73 kDa
Dry ice
2044679-53-8
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
MCLA-117
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q5QGZ9
Human
Unconjugated
Monoclonal
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
CLEC12A / CD371
Please avoid freeze-thaw cycles.